Morgan Stanley
TBIO

Morgan Stanley’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

Morgan Stanley’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10
Closed -$185 – 7935
2023
Q3 		$185 Sell
10
-178
-95% -$4.33K ﹤0.01% 7391
2023
Q2 		$5.34K Sell
188
-96
-34% -$3.83K ﹤0.01% 6973
2023
Q1 		$15.8K Buy
284
+193
+212% +$6.83K ﹤0.01% 6714
2022
Q4 		$1.97K Sell
91
-285
-76% -$7.75K ﹤0.01% 7379
2022
Q3 		$11K Sell
376
-1,259
-77% -$44.3K ﹤0.01% 7049
2022
Q2 		$52K Buy
1,635
+927
+131% +$64K ﹤0.01% 6595
2022
Q1 		$68K Sell
708
-41
-5% -$6.22K ﹤0.01% 6546
2021
Q4 		$146K Buy
749
+281
+60% +$43.7K ﹤0.01% 6230
2021
Q3 		$94K Buy
468
+417
+818% +$106K ﹤0.01% 6418
2021
Q2 		$20K Buy
+51
New +$18K ﹤0.01% 7014

Other funds holding TBIO

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley's TBIO Position: Q4 2023 in Review

Morgan Stanley sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q4 2023, closing a stake of 10 shares — an estimated $185 sold.

Morgan Stanley first reported a position in TBIO in Q2 2021 and held it in 10 quarters. The position peaked at $146K in Q4 2021. 24 funds tracked by Wall St. Rank hold TBIO as of Q4 2023.

  • Morgan Stanley reported no remaining Telesis Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 10 Telesis Bio, Inc. Common Stock shares in Q4 2023, an estimated $185.
  • Morgan Stanley first reported a position in Telesis Bio, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • Morgan Stanley's Telesis Bio, Inc. Common Stock position peaked at $146K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.